Immutep Secures A$0.86M R&D Tax Rebate for 2025 Fiscal Year
Event summary
- Immutep received A$856,669 cash rebate from Australia’s R&D tax incentive program for 2025 fiscal year.
- Approval from AusIndustry allowed overseas R&D activities to qualify for the incentive.
- Company also eligible for French CIR and German Forschungszulage tax incentives.
- Funds will support R&D for product candidates efti and IMP761, extending cash reach into 1H 2028.
The big picture
Immutep’s ability to secure R&D tax incentives across multiple jurisdictions highlights the strategic importance of non-dilutive funding for late-stage biotech companies. The move comes as immunotherapy firms increasingly rely on government programs to extend cash runways while advancing clinical pipelines. The A$0.86M rebate represents a small but meaningful boost to Immutep’s financial flexibility as it navigates the capital-intensive phase of product development.
What we're watching
- Cash Runway
- Whether the A$0.86M rebate and other tax incentives will sufficiently extend Immutep’s cash reach into 2028 as projected.
- Regulatory Dynamics
- The pace at which Immutep can secure additional R&D tax incentives from other jurisdictions.
- R&D Execution
- How the non-dilutive funding will accelerate the development of efti and IMP761.
Related topics